RxSight (NASDAQ:RXST) & Monogram Orthopaedics (NASDAQ:MGRM) Head-To-Head Comparison

RxSight (NASDAQ:RXST) and Monogram Orthopaedics (NASDAQ:MGRM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.

Risk and Volatility

RxSight has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, Monogram Orthopaedics has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500.

Institutional and Insider Ownership

78.8% of RxSight shares are held by institutional investors. Comparatively, 0.5% of Monogram Orthopaedics shares are held by institutional investors. 9.6% of RxSight shares are held by insiders. Comparatively, 28.1% of Monogram Orthopaedics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares RxSight and Monogram Orthopaedics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$139.93 million	2.63	-$27.45 million	($0.80)	-11.26
Monogram Orthopaedics	$370,000.00	647.88	-$16.33 million	($0.50)	-11.80

Monogram Orthopaedics has lower revenue, but higher earnings than RxSight. Monogram Orthopaedics is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for RxSight and Monogram Orthopaedics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	2	9	1	0	1.92
Monogram Orthopaedics	0	0	1	1	3.50

RxSight presently has a consensus target price of $10.00, suggesting a potential upside of 10.99%. Monogram Orthopaedics has a consensus target price of $5.40, suggesting a potential downside of 8.47%. Given RxSight’s higher possible upside, equities research analysts clearly believe RxSight is more favorable than Monogram Orthopaedics.

Profitability

This table compares RxSight and Monogram Orthopaedics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RxSight	-21.93%	-11.56%	-10.31%
Monogram Orthopaedics	N/A	-126.82%	-96.87%

About RxSight

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

About Monogram Orthopaedics

Monogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was founded in 2015 and is headquartered in Austin, Texas.